Share this article

US-based medical device firm NuVasive has acquired interbody implants provider Vertera Spine, expanding its advanced materials science portfolio.

Financial details of the deal have not been disclosed.

Vertera uses patented porous polyetheretherketone (PEEK) technology to develop and commercialise implants for spinal fusion.

Using a specific processing method to retain strength and durability, the technology offers a three-dimensional porous PEEK architecture that is said to aid the stimulation of bone ingrowth in patients who have undergone spinal fusion procedures.

The acquisition will now allow NuVasive to deliver porous interbody technology across PEEK and titanium materials to serve different needs and preferences of surgeons for interbody implants.

“This helps to create more predictable, improved outcomes for patients undergoing spine surgery.”

NuVasive chairman and CEO Gregory Lucier said: “With the addition of porous PEEK technology, NuVasive takes the next step in building out its advanced materials science technology focused on delivering the highest level of scientifically driven properties for best spinal fusion rates, including porosity, visualisation, surface, and structure.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

“This, in turn, helps to create more predictable, improved outcomes for patients undergoing spine surgery.”

The firm plans to add Vertera’s products to its commercial offerings and further use the porous PEEK technology during development of new products.

Vertera’s current interbody product portfolio includes the US Food and Drug Administration (FDA) cleared COHERE cervical interbody fusion device and COALESCE device that is designed for anterior, transforaminal, posterior and lateral lumbar interbody fusion procedures.

The firm is planning to secure extensions of COALESCE for posterior and transforaminal lumbar interbody fusion.